Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC — Stella

Recruiting

Back to Nasopharyngeal Carcinoma trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Large-scale testing

Sponsor

Fudan University

Enrollment target

~266 participants

Started

December 2023

Primary completion

December 2026

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov